A combination of the identified 3 genes in BM+ and 8 genes in BM showed better prediction than did each individual gene, and this combination can be used as a training set.
Aim:A high expression of epidermal growth factor receptor (EGFR) is found in most human epithelial tumors, including nasopharyngeal carcinomas (NPC). The overexpression of EGFR has been shown to play an influential role in tumorigenesis and the progression of malignant tumors. Therefore, blocking EGFR might be a potential targeted treatment for NPC. Nimotuzumab is an anti-EGFR monoclonal antibody that exhibits remarkable anti-proliferative, anti-angiogenic, and pro-apoptotic effects. Methods: Here we report five patients with loco-regionally advanced NPC, treated with nimotuzumab 100 mg i.v./week for 8 weeks in combination with radiotherapy in a total dose of 70-74 Gy. Results: A computed tomography evaluation of all five patients showed that the primary tumor volume was reduced, ranging from 64.1 to 98% and the nodal volume was reduced by 90.7-100%. No severe adverse events related to nimotuzumab were observed. Conclusion: The use of nimotuzumab in combination with radiotherapy was potentially beneficial and safe for patients with advanced NPC.
Tuberculosis (TB) is a disease with high morbidity and mortality resulting from infection by Mycobacterium tuberculosis. TB can disseminate to any organ system of the body resulting in extrapulmonary tuberculosis. Interestingly, CA-125, which is a biomarker for some cancer, also rises in benign diseases such as pulmonary and extrapulmonary tuberculosis which may complicate diagnosis. In this case report, we present an abdominal tuberculosis patient that was initially presented as ovarian cancer. Case Report: A 30-year-old woman admitted to the emergency department with chief complaint of fatigue and shortness of breath since 3 months ago. She had lost around 20 kg weight in the past 5 months. She was previously suspected with ovarian cancer because of the characteristic features of malignancy, high levels of CA-125, and positive PET scan. She was later diagnosed with abdominal TB. Subsequently, the patient was given anti-TB drugs, and the patient showed clinical improvement.
Conclusion:In the case of an elevated CA-125, clinicians should consider extrapulmonary TB as a differential diagnosis of ovarian cancer, especially in countries with high burden of tuberculosis.
There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.
Introduction: Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma, but it represents only a small portion of soft tissue sarcoma in adult population. There is a treatment protocol based on Intergroup Rhabdomyosarcoma Study (IRS) that provides satisfactory results in treating RMS in children, but there is only limited evidence regarding the outcome and prognosis in extrapolating the IRS protocol to treat RMS in adults. We report a case of adult pleomorphic RMS treated with multidisciplinary approach and the results we have obtained. Case presentation: A 48-year-old woman was admitted in February 2011 due to a painful mass on her left thigh. Diagnosis of pleomorphic rhabdomyosarcoma was made by histopathology and immunohistochemistry. After multimodal treatment that includes Trans-Arterial Chemotherapy Infusion, Cryosurgery, and wide excision surgery, our patient remains disease-free as of the latest annual follow up examination on June 2017. Conclusions: The pleomorphic type of Rhabdomyosarcoma is very rare in adults and is often associated with a poor prognosis. In our case, a multidisciplinary approach with multimodal treatment provides excellent result, even after a routine follow up spanning through six years.
S464to the extremes of ranges, and start date for length of survival: method 1. progression after second line therapy or three weeks post last dose of chemo for control group and start date of erlotinib for treatment group; method 2. last date of second line therapy for both groups. 75 control and 70 erlotinib patients were included in the analysis. Results are presented in the table. The Incremental Cost-Effectiveness Ratio (ICER) was $28,516 per life-year-gained under method 1, and $17,632 under method 2. The erlotinib group had similar one year OS compared to literature (36 vs. 31%). Method 1: Parameter Controls (N=75) Erlotinib (N=70) Area under curve (months) 3.86 7.91 p-value (log-rank test) <0.001 Median Survival months (95% CI) 2.56 (2.04-4.8) 4.73 (2.89-14.7) 1-year OS % (95% CI) 0.
Penelitian ini bertujuan untuk mengetahui dan menganalisis penatausahaan aset tetap daerah berdasarkan Permendagri Nomor 19 Tahun 2016 pada Biro Umum Sekretariat Daerah Provinsi Sulawesi Tenggara. Penelitian ini menggunakan pendekatan deskriptif kualitatif. Teknik pengumpulan data yang digunakan adalah observasi dokumen, wawancara, dokumentasi, dan studi kepustakaan. Hasil penelitian menunjukkan bahwa penatausahaan aset tetap daerah pada Biro Umum Sekretariat Daerah Provinsi Sulawesi Tenggara dilihat dari indikator pembukuan, inventarisasi dan pelaporan telah mengikuti ketentuan penatausahaan dalam Permendagri Nomor 19 Tahun 2016, yang mana Kepala Biro Umum melalui Pengurus Barang Pengguna telah rutin melakukan kegiatan pendaftaran dan pencatatan aset tetap daerah menurut penggolongan dan kodefikasi barang, telah melakukan inventarisasi aset tetap daerah melalui tim inventarisasi sekali dalam 5 (lima) tahun atau setiap tahun untuk aset tetap berupa Konstruksi dalam Pengerjaan, dan membuat Laporan Realisasi Barang semesteran dan tahunan yang rutin dilaporkan kepada Sekretaris Daerah Provinsi Sulawesi Tenggara melalui Kabid. Aset BPKAD Provinsi Sulawesi Tenggara.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.